London, UK, Friday 30 May 2025 – Today, AstraZeneca announced that the National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending Forxiga ...

BELGRADE, Serbia—Dapagliflozin (Farxiga; AstraZeneca) does not further improve quality of ... or impaired LVEF) to dapagliflozin 10 mg once daily or standard care, was the first trial to extend those ...

Participants were randomly assigned to receive 10 mg dapagliflozin (AstraZeneca; IN, USA) or matching placebo once daily in a 1:1 ratio. The randomisation schedules were generated using a computer ...

We compared the dapagliflozin 10 mg (n = 179) and saxagliptin 5 mg (n = 176 ... This analysis was supported by AstraZeneca. Editorial support was provided by Shelley Narula of in Science ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

Originally designed as glucose-lowering medications, SGLT2 inhibitors provide benefits across the cardio-renal-metabolic ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

AstraZeneca is putting the pedal to the metal to drive up early detection of prostate cancer. The British pharma—which sells Lynparza as a prostate cancer treatment and is also testing its ...

A Google Translate screenshot correctly shows that the name of the pharmaceutical company AstraZeneca, when written as “A stra ze neca,” means “a road to death” in Latin. We reached out to ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action ...